Filing Flows › Comparisons › CRSP vs EDIT
Crispr Therapeutics AG vs Editas Medicine: CRSP and EDIT compared
Crispr Therapeutics AG is the larger company: $12.7M of revenue in its latest quarter (Q3 2026) against $11.9M for Editas Medicine (Q2 2026). Crispr Therapeutics AG is growing faster (14× against +232% a year earlier).
Where the money goes: CRSP and EDIT
Crispr Therapeutics AG (CRSP) · Q3 2026
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
Editas Medicine (EDIT) · Q2 2026
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.
| Crispr Therapeutics AG (CRSP) | Editas Medicine (EDIT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $12.7M | $11.9M |
| Revenue growth, Y/Y | 14× | +232% |
| Operating margin | n/m | -156.0% |
| Net earnings | −$111M | −$18.2M |
| Net margin | -879.6% | -153.3% |
| Operating cash flow | −$89.7M | −$29.6M |
Where the revenue comes from
Crispr Therapeutics AG
- Collaboration Revenue: $12.3M (97%)
- Grant: $346K (3%)
Questions
Which is bigger, Crispr Therapeutics AG or Editas Medicine?
Crispr Therapeutics AG is the larger company: $12.7M of revenue in its latest quarter (Q3 2026) against $11.9M for Editas Medicine (Q2 2026).
Is Crispr Therapeutics AG or Editas Medicine growing faster?
Crispr Therapeutics AG is growing faster (14× against +232% a year earlier).
More: Crispr Therapeutics AG earnings · how Crispr Therapeutics AG makes money · Editas Medicine earnings · how Editas Medicine makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Aug 5, 2026). Fiscal quarters can end on different dates. Not investment advice.